HRP20161171T1 - AMIDINSKI SUPSTITUIRANI β-LAKTAMSKI SPOJEVI, NJIHOVA PRIPRAVA I UPOTREBA KAO ANTIBAKTERIJSKIH SREDSTAVA - Google Patents
AMIDINSKI SUPSTITUIRANI β-LAKTAMSKI SPOJEVI, NJIHOVA PRIPRAVA I UPOTREBA KAO ANTIBAKTERIJSKIH SREDSTAVA Download PDFInfo
- Publication number
- HRP20161171T1 HRP20161171T1 HRP20161171TT HRP20161171T HRP20161171T1 HR P20161171 T1 HRP20161171 T1 HR P20161171T1 HR P20161171T T HRP20161171T T HR P20161171TT HR P20161171 T HRP20161171 T HR P20161171T HR P20161171 T1 HRP20161171 T1 HR P20161171T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino
- thiazol
- imino
- ethoxy
- oxo
- Prior art date
Links
- -1 beta-lactam compounds Chemical class 0.000 title claims 41
- 150000001409 amidines Chemical group 0.000 title 1
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 39
- 125000001424 substituent group Chemical group 0.000 claims 31
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 25
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 20
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 17
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 16
- 235000019260 propionic acid Nutrition 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 16
- 239000012453 solvate Substances 0.000 claims 16
- 229910052736 halogen Chemical group 0.000 claims 15
- 150000002367 halogens Chemical group 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 14
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 12
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 11
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 10
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 9
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 9
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 8
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims 8
- 125000004432 carbon atom Chemical group C* 0.000 claims 8
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 6
- 208000035143 Bacterial infection Diseases 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 229940126601 medicinal product Drugs 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical group C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- UBHAMQJKGHLMIT-WVBONNFESA-N (2S,3S)-3-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(4-carbamimidoyl-3-hydroxyphenoxy)ethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\c1csc(N)n1)=N/OCCOc1ccc(C(N)=N)c(O)c1 UBHAMQJKGHLMIT-WVBONNFESA-N 0.000 claims 1
- GFTKQOZYMBRHLW-QMRYPOTESA-N (2r,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(4-carbamimidoylphenoxy)ethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=N)C=C1 GFTKQOZYMBRHLW-QMRYPOTESA-N 0.000 claims 1
- OVPRZFMRNNLBGK-QAAQHXJBSA-N (2s)-2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(3s)-2,2-dimethyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-3-[4-[n'-[(3r)-pyrrolidin-3-yl]carbamimidoyl]phenoxy]propanoic acid Chemical compound O=C1N(S(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/O[C@H](C(O)=O)COC1=CC=C(C(N)=N[C@H]2CNCC2)C=C1 OVPRZFMRNNLBGK-QAAQHXJBSA-N 0.000 claims 1
- KYGFNBJHBRRFJQ-LHSYBBSFSA-N (2s)-2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(3s)-2,2-dimethyl-4-oxo-1-sulfooxyazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-3-[4-(n'-piperidin-4-ylcarbamimidoyl)phenoxy]propanoic acid Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/O[C@H](C(O)=O)COC1=CC=C(C(N)=NC2CCNCC2)C=C1 KYGFNBJHBRRFJQ-LHSYBBSFSA-N 0.000 claims 1
- MQMWFTDIWHTOAU-KUWBHHGFSA-N (2s)-2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(3s)-2,2-dimethyl-4-oxo-1-sulfooxyazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-3-[4-[n'-(azetidin-3-yl)carbamimidoyl]phenoxy]propanoic acid Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/O[C@H](C(O)=O)COC1=CC=C(C(N)=NC2CNC2)C=C1 MQMWFTDIWHTOAU-KUWBHHGFSA-N 0.000 claims 1
- MPYLZKVUNCKVGE-DEFDSVGDSA-N (2s)-2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(3s)-2,2-dimethyl-4-oxo-1-sulfooxyazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-3-[4-[n'-(piperidin-2-ylmethyl)carbamimidoyl]phenoxy]propanoic acid Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/O[C@H](C(O)=O)COC1=CC=C(C(N)=NCC2NCCCC2)C=C1 MPYLZKVUNCKVGE-DEFDSVGDSA-N 0.000 claims 1
- HVWZESLBVALISX-KUWBHHGFSA-N (2s)-2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(3s)-2,2-dimethyl-4-oxo-1-sulfooxyazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-3-[4-[n'-[2-(methylamino)ethyl]carbamimidoyl]phenoxy]propanoic acid Chemical compound C1=CC(C(N)=NCCNC)=CC=C1OC[C@@H](C(O)=O)O\N=C(C=1N=C(N)SC=1)/C(=O)N[C@H]1C(C)(C)N(OS(O)(=O)=O)C1=O HVWZESLBVALISX-KUWBHHGFSA-N 0.000 claims 1
- ZDWQZOLSJSBMEM-KXLHIESCSA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(4-carbamimidoylphenyl)methoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCC1=CC=C(C(N)=N)C=C1 ZDWQZOLSJSBMEM-KXLHIESCSA-N 0.000 claims 1
- JLGWQOHUGYAIPH-FIWXLPQASA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[1-(4-carbamimidoylphenoxy)-2-methylpropan-2-yl]oxyiminoacetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OC(C)(C)COC1=CC=C(C(N)=N)C=C1 JLGWQOHUGYAIPH-FIWXLPQASA-N 0.000 claims 1
- NZKYITYKDCIWHL-OQMYIJJMSA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(2-bromo-4-carbamimidoylphenoxy)ethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=N)C=C1Br NZKYITYKDCIWHL-OQMYIJJMSA-N 0.000 claims 1
- DTMMNMMGXGFBAO-AAGJFWKWSA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(3-carbamimidoylphenoxy)ethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=CC(C(N)=N)=C1 DTMMNMMGXGFBAO-AAGJFWKWSA-N 0.000 claims 1
- XETHAHFSRGGEIN-OQMYIJJMSA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(4-carbamimidoyl-2-chlorophenoxy)ethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=N)C=C1Cl XETHAHFSRGGEIN-OQMYIJJMSA-N 0.000 claims 1
- UGTLYPYZRIEXBG-OQMYIJJMSA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(4-carbamimidoyl-2-fluorophenoxy)ethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=N)C=C1F UGTLYPYZRIEXBG-OQMYIJJMSA-N 0.000 claims 1
- SKQTUKQCAGKOCN-MKAGAKJLSA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(4-carbamimidoyl-3-methylphenoxy)ethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=N)C(C)=C1 SKQTUKQCAGKOCN-MKAGAKJLSA-N 0.000 claims 1
- HVSMMSWRHJEZMN-OSPXMHHYSA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(4-carbamimidoylphenoxy)ethoxyimino]acetyl]amino]-2-carbamoyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@H](C(=O)N)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=N)C=C1 HVSMMSWRHJEZMN-OSPXMHHYSA-N 0.000 claims 1
- GFTKQOZYMBRHLW-AAGJFWKWSA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(4-carbamimidoylphenoxy)ethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=N)C=C1 GFTKQOZYMBRHLW-AAGJFWKWSA-N 0.000 claims 1
- FHYHFHDLQKADIP-AAGJFWKWSA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(4-carbamimidoylphenyl)sulfanylethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCSC1=CC=C(C(N)=N)C=C1 FHYHFHDLQKADIP-AAGJFWKWSA-N 0.000 claims 1
- VRRBINQEFCBPQZ-XWPUJFQCSA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(5-carbamimidoyl-1-methylpyrazol-3-yl)oxyethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=NN(C)C(C(N)=N)=C1 VRRBINQEFCBPQZ-XWPUJFQCSA-N 0.000 claims 1
- ZTQPFIAOJPJHSN-XWPUJFQCSA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(5-carbamimidoyl-2-methylpyrazol-3-yl)oxyethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC(C(N)=N)=NN1C ZTQPFIAOJPJHSN-XWPUJFQCSA-N 0.000 claims 1
- YIHMTJLXOWYZNF-DLGGPMKASA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(5-carbamimidoylpyridin-2-yl)oxyethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=N)C=N1 YIHMTJLXOWYZNF-DLGGPMKASA-N 0.000 claims 1
- UHTJHBHEACMBDR-GNAXJGCWSA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-[(4-carbamimidoyl-1,3-thiazol-2-yl)oxy]ethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=NC(C(N)=N)=CS1 UHTJHBHEACMBDR-GNAXJGCWSA-N 0.000 claims 1
- MQRQPIRWCADKNJ-KXLHIESCSA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-[(4-carbamimidoylthiophen-2-yl)methoxy]ethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOCC1=CC(C(N)=N)=CS1 MQRQPIRWCADKNJ-KXLHIESCSA-N 0.000 claims 1
- OSWWZHFQGVDOPP-IKGNQYEOSA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-[(5-carbamimidoyl-1,3,4-thiadiazol-2-yl)oxy]ethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=NN=C(C(N)=N)S1 OSWWZHFQGVDOPP-IKGNQYEOSA-N 0.000 claims 1
- DQCZMZSVMVBQJP-FIWXLPQASA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-[4-[(z)-n'-formamidocarbamimidoyl]phenoxy]ethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(\N)=N\NC=O)C=C1 DQCZMZSVMVBQJP-FIWXLPQASA-N 0.000 claims 1
- QOVJNCBNZXHFDB-AAGJFWKWSA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-[4-[(z)-n'-hydroxycarbamimidoyl]phenoxy]ethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(\N)=N\O)C=C1 QOVJNCBNZXHFDB-AAGJFWKWSA-N 0.000 claims 1
- HRSSWXGPJZJSAQ-JUBZOZOPSA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-[4-[n'-(2-hydroxyethyl)carbamimidoyl]phenoxy]ethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=NCCO)C=C1 HRSSWXGPJZJSAQ-JUBZOZOPSA-N 0.000 claims 1
- VGVNTWMZHJDLPQ-ZIPFDZITSA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-[4-carbamimidoyl-2-(hydroxymethyl)phenoxy]ethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=N)C=C1CO VGVNTWMZHJDLPQ-ZIPFDZITSA-N 0.000 claims 1
- MMPRWBWQMNJEBU-FIWXLPQASA-N (2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[3-[4-(diaminomethylideneamino)phenoxy]propoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCCOC1=CC=C(N=C(N)N)C=C1 MMPRWBWQMNJEBU-FIWXLPQASA-N 0.000 claims 1
- YJACTACBEKOFKK-RUHVQPKUSA-N (2s,3s)-3-[[(2z)-2-(2-amino-5-chloro-1,3-thiazol-4-yl)-2-[2-(4-carbamimidoylphenoxy)ethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C1=C(SC(N)=N1)Cl)=N/OCCOC1=CC=C(C(N)=N)C=C1 YJACTACBEKOFKK-RUHVQPKUSA-N 0.000 claims 1
- FMFTXNRDPROUFR-OQMYIJJMSA-N (2s,3s)-3-[[(2z)-2-[2-(2-amino-4-carbamimidoylphenoxy)ethoxyimino]-2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=N)C=C1N FMFTXNRDPROUFR-OQMYIJJMSA-N 0.000 claims 1
- LVMHGUJLUPQJSK-QEYCWDPCSA-N (2s,3s)-3-[[(2z)-2-[2-[4-(2-amino-2-iminoethyl)phenoxy]ethoxyimino]-2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(CC(N)=N)C=C1 LVMHGUJLUPQJSK-QEYCWDPCSA-N 0.000 claims 1
- VCACGBRMRUYENY-IEGQBCMDSA-N (2s,3s)-3-[[(2z)-2-[2-[4-[(z)-c-aminocarbonohydrazonoyl]phenoxy]ethoxyimino]-2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonic acid Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(\N)=N\N)C=C1 VCACGBRMRUYENY-IEGQBCMDSA-N 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- YOTRRQGYOHCXKO-YKVGDQEKSA-N 2-[[amino-[4-[2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(3s)-2,2-dimethyl-4-oxo-1-sulfooxyazetidin-3-yl]amino]-2-oxoethylidene]amino]oxyethoxy]phenyl]methylidene]amino]acetic acid Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=NCC(O)=O)C=C1 YOTRRQGYOHCXKO-YKVGDQEKSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- NYNWPBAFYJGUTB-CWEJAESISA-N NC=1SC=C(N1)/C(/C(=O)N[C@H]1C(N(C1=O)O)(C)C)=N/OCCOC1=CC=C(C=C1)C(NCCNC=N)=N Chemical compound NC=1SC=C(N1)/C(/C(=O)N[C@H]1C(N(C1=O)O)(C)C)=N/OCCOC1=CC=C(C=C1)C(NCCNC=N)=N NYNWPBAFYJGUTB-CWEJAESISA-N 0.000 claims 1
- HRXVAIQXRXNRJT-VLKICEKPSA-N O=C1N(OCS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\c1csc(N)n1)=N/OCc1ccc(C(N)=N)cc1 Chemical compound O=C1N(OCS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\c1csc(N)n1)=N/OCc1ccc(C(N)=N)cc1 HRXVAIQXRXNRJT-VLKICEKPSA-N 0.000 claims 1
- OQTYUNDCTQEHCJ-DBPQUTDOSA-N O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\c1csc(N)n1)=N/OC(CC(O)=O)COc1ccc(C(N)=N)cc1 Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\c1csc(N)n1)=N/OC(CC(O)=O)COc1ccc(C(N)=N)cc1 OQTYUNDCTQEHCJ-DBPQUTDOSA-N 0.000 claims 1
- VRCDOMCODJWBBZ-OKXLPGIMSA-N O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\c1csc(N)n1)=N/O[C@@H](C(O)=O)COc1ccc(C(=N)NCc2ncc[nH]2)cc1 Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\c1csc(N)n1)=N/O[C@@H](C(O)=O)COc1ccc(C(=N)NCc2ncc[nH]2)cc1 VRCDOMCODJWBBZ-OKXLPGIMSA-N 0.000 claims 1
- ZLTQJRXVMLJYCT-MCDHVSOPSA-N O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\c1csc(N)n1)=N/O[C@H](C(O)=O)COc1ccc(C(=N)NC2CCCNC2)cc1 Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\c1csc(N)n1)=N/O[C@H](C(O)=O)COc1ccc(C(=N)NC2CCCNC2)cc1 ZLTQJRXVMLJYCT-MCDHVSOPSA-N 0.000 claims 1
- ZLTQJRXVMLJYCT-PRRNWXPFSA-N O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\c1csc(N)n1)=N/O[C@H](C(O)=O)COc1ccc(C(=N)N[C@@H]2CCCNC2)cc1 Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\c1csc(N)n1)=N/O[C@H](C(O)=O)COc1ccc(C(=N)N[C@@H]2CCCNC2)cc1 ZLTQJRXVMLJYCT-PRRNWXPFSA-N 0.000 claims 1
- SXLHZZPCMHMQFF-CWEJAESISA-N O=C1N(S(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\c1csc(N)n1)=N/OCCOc1ccc(C(=N)NC2CNNC2)cc1 Chemical compound O=C1N(S(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\c1csc(N)n1)=N/OCCOc1ccc(C(=N)NC2CNNC2)cc1 SXLHZZPCMHMQFF-CWEJAESISA-N 0.000 claims 1
- BLCYGQVKTALHJC-OSVZUKHBSA-N O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\c1csc(N)n1)=N/OCCOc1cc(C(N)=N)no1 Chemical compound O=C1N(S(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\c1csc(N)n1)=N/OCCOc1cc(C(N)=N)no1 BLCYGQVKTALHJC-OSVZUKHBSA-N 0.000 claims 1
- SYZVWJMXJFBLIC-QMRYPOTESA-N [(2r,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(4-carbamimidoylphenoxy)ethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)[C@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=N)C=C1 SYZVWJMXJFBLIC-QMRYPOTESA-N 0.000 claims 1
- SYZVWJMXJFBLIC-AAGJFWKWSA-N [(2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(4-carbamimidoylphenoxy)ethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=N)C=C1 SYZVWJMXJFBLIC-AAGJFWKWSA-N 0.000 claims 1
- MMPSIEBNJKMXOF-MKAGAKJLSA-N [(2s,3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(4-carbamimidoylphenoxy)ethoxyimino]acetyl]amino]-2-methyl-4-oxoazetidin-1-yl]oxymethanesulfonic acid Chemical compound O=C1N(OCS(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=N)C=C1 MMPSIEBNJKMXOF-MKAGAKJLSA-N 0.000 claims 1
- NYBYNTFVQYHGIP-PZGASYLGSA-N [(2s,3s)-3-[[(2z)-2-[2-[4-[n'-(2-aminoethyl)carbamimidoyl]phenoxy]ethoxyimino]-2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-2-methyl-4-oxoazetidin-1-yl]oxymethanesulfonic acid Chemical compound O=C1N(OCS(O)(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=NCCN)C=C1 NYBYNTFVQYHGIP-PZGASYLGSA-N 0.000 claims 1
- VLSQERXVFKOWLY-SCSAIBSYSA-N [(3S)-3-(2-amino-2-oxoethyl)-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound CC1(N(C([C@H]1CC(=O)N)=O)OS(=O)(=O)O)C VLSQERXVFKOWLY-SCSAIBSYSA-N 0.000 claims 1
- FRXMKZSHABUSIH-YZVKNKPJSA-N [(3S)-3-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(6-carbamimidoyl-5-hydroxypyridin-3-yl)oxyethoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\c1csc(N)n1)=N/OCCOc1cnc(C(N)=N)c(O)c1 FRXMKZSHABUSIH-YZVKNKPJSA-N 0.000 claims 1
- FFCNEMJFZGPFRF-IFUVNARDSA-N [(3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(4-carbamimidoylphenyl)methoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCC1=CC=C(C(N)=N)C=C1 FFCNEMJFZGPFRF-IFUVNARDSA-N 0.000 claims 1
- ILSDAURZRGBRFR-UWLYNBDASA-N [(3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(2-carbamimidoylpyridin-4-yl)oxyethoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=NC(C(N)=N)=C1 ILSDAURZRGBRFR-UWLYNBDASA-N 0.000 claims 1
- LZNPBCGXCLQRKF-VLKICEKPSA-N [(3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(4-carbamimidoylphenoxy)ethoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=N)C=C1 LZNPBCGXCLQRKF-VLKICEKPSA-N 0.000 claims 1
- PPRLWQYPXRWUQS-VLKICEKPSA-N [(3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(4-carbamimidoylphenyl)sulfanylethoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCSC1=CC=C(C(N)=N)C=C1 PPRLWQYPXRWUQS-VLKICEKPSA-N 0.000 claims 1
- SDXKOGVXUZWXHC-UWLYNBDASA-N [(3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(6-carbamimidoylpyridin-3-yl)oxyethoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=N)N=C1 SDXKOGVXUZWXHC-UWLYNBDASA-N 0.000 claims 1
- HHSIGOWCXLQBNP-LRAQNNFBSA-N [(3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-[(2-carbamimidoyl-5-methyl-1,3-thiazol-4-yl)oxy]ethoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound S1C(C(N)=N)=NC(OCCO\N=C(/C(=O)N[C@H]2C(N(OS(O)(=O)=O)C2=O)(C)C)C=2N=C(N)SC=2)=C1C HHSIGOWCXLQBNP-LRAQNNFBSA-N 0.000 claims 1
- LGPRXQZIUDKXRO-YKVGDQEKSA-N [(3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-[4-(4,5-dihydro-1h-imidazol-2-yl)phenoxy]ethoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C=2NCCN=2)C=C1 LGPRXQZIUDKXRO-YKVGDQEKSA-N 0.000 claims 1
- NYVDZFBJVHQRDS-YGPWIVTJSA-N [(3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-[4-(n'-piperidin-4-ylcarbamimidoyl)phenoxy]ethoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=NC2CCNCC2)C=C1 NYVDZFBJVHQRDS-YGPWIVTJSA-N 0.000 claims 1
- JYXRWNBDPAGPRM-CWEJAESISA-N [(3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-[4-[n'-(1,3-diaminopropan-2-yl)carbamimidoyl]phenoxy]ethoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=NC(CN)CN)C=C1 JYXRWNBDPAGPRM-CWEJAESISA-N 0.000 claims 1
- KLGJYSTYTMQDOO-IUMFXXMVSA-N [(3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-[4-[n'-[(3s)-1-ethanimidoylpyrrolidin-3-yl]carbamimidoyl]phenoxy]ethoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound C1N(C(=N)C)CC[C@@H]1N=C(N)C(C=C1)=CC=C1OCCO\N=C(C=1N=C(N)SC=1)/C(=O)N[C@H]1C(C)(C)N(OS(O)(=O)=O)C1=O KLGJYSTYTMQDOO-IUMFXXMVSA-N 0.000 claims 1
- IXUCHBUKQYYVCQ-JUMRHNHYSA-N [(3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-[4-[n'-[(3s)-pyrrolidin-3-yl]carbamimidoyl]phenoxy]ethoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=N[C@@H]2CNCC2)C=C1 IXUCHBUKQYYVCQ-JUMRHNHYSA-N 0.000 claims 1
- MOKJUGMQQNXAFQ-AONZUBIFSA-N [(3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-[4-[n'-[2-(diaminomethylideneamino)ethyl]carbamimidoyl]phenoxy]ethoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=NCCN=C(N)N)C=C1 MOKJUGMQQNXAFQ-AONZUBIFSA-N 0.000 claims 1
- QQELDOOYSFPGBG-LMITWDTESA-N [(3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-[4-[n'-[2-(dimethylamino)ethyl]carbamimidoyl]phenoxy]ethoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound C1=CC(C(N)=NCCN(C)C)=CC=C1OCCO\N=C(C=1N=C(N)SC=1)/C(=O)N[C@H]1C(C)(C)N(OS(O)(=O)=O)C1=O QQELDOOYSFPGBG-LMITWDTESA-N 0.000 claims 1
- HPZWNWQNCPATTB-ZASWBZMTSA-N [(3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[3-(4-carbamimidoylphenoxy)propoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCCOC1=CC=C(C(N)=N)C=C1 HPZWNWQNCPATTB-ZASWBZMTSA-N 0.000 claims 1
- XCAVYCWFYSZJEL-DXKFBMHFSA-N [(3s)-3-[[(2z)-2-[1-amino-3-(4-carbamimidoylphenoxy)-1-oxopropan-2-yl]oxyimino-2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OC(C(N)=O)COC1=CC=C(C(N)=N)C=C1 XCAVYCWFYSZJEL-DXKFBMHFSA-N 0.000 claims 1
- DKOMWZLYEIWRDV-BGYQVPDLSA-N [(3s)-3-[[(2z)-2-[2-[4-(5-amino-1,4,5,6-tetrahydropyrimidin-2-yl)phenoxy]ethoxyimino]-2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C=2NCC(N)CN=2)C=C1 DKOMWZLYEIWRDV-BGYQVPDLSA-N 0.000 claims 1
- RTROUCRQSDIXNM-LBCBNVEPSA-N [(3s)-3-[[(2z)-2-[2-[4-[5-(aminomethyl)-4,5-dihydro-1h-imidazol-2-yl]phenoxy]ethoxyimino]-2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C=2NC(CN)CN=2)C=C1 RTROUCRQSDIXNM-LBCBNVEPSA-N 0.000 claims 1
- ZDQOGGNMPDTALG-MDFSBEDCSA-N [(3s)-3-[[(2z)-2-[2-[4-[n'-(2-aminoethyl)carbamimidoyl]phenoxy]ethoxyimino]-2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=NCCN)C=C1 ZDQOGGNMPDTALG-MDFSBEDCSA-N 0.000 claims 1
- CVXLKWZFRXEJAU-FQWHGFDNSA-N [(3s)-3-[[(2z)-2-[2-[4-[n'-[(2r)-1-amino-3-hydroxypropan-2-yl]carbamimidoyl]phenoxy]ethoxyimino]-2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCCOC1=CC=C(C(N)=N[C@H](CN)CO)C=C1 CVXLKWZFRXEJAU-FQWHGFDNSA-N 0.000 claims 1
- TVKLJLGMUIRXLS-DICXZTSXSA-N [3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-(4-carbamimidoylphenoxy)ethoxyimino]acetyl]amino]-2-oxo-1-azaspiro[3.4]octan-1-yl] hydrogen sulfate Chemical compound C1=CC(C(=N)N)=CC=C1OCCO\N=C(C=1N=C(N)SC=1)/C(=O)NC1C2(CCCC2)N(OS(O)(=O)=O)C1=O TVKLJLGMUIRXLS-DICXZTSXSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003781 beta lactamase inhibitor Substances 0.000 claims 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Claims (20)
1. Spoj formule
[image]
,
naznačen time što
R1 i R2 međusobno neovisno predstavljaju vodik, aminokarbonil ili (C1-C4)-alkil, ili
R1 i R2 zajedno s atomom ugljika na kojeg su vezani tvore (C3-C8)-cikloalkil,
R3 predstavlja -(CH2)m-(SO2)OH ili -O-(CH2)o-(SO2)OH,
gdje m i o međusobno neovisno predstavljaju cijeli broj 0, 1, 2 ili 3, i
gdje bilo koja skupina CH2 koja se nalazi u ostacima koje predstavlja R3 može biti supstituirana s jednim ili dva (C1-C4)-alkilna ostatka,
X predstavlja CR4 ili N,
R4 predstavlja vodik ili halogen,
Z predstavlja vezu ili alkilni lanac s jednim, dva, tri ili četiri atoma ugljika,
gdje alkilni lanac može biti supstituiran s jednim, dva, tri ili četiri supstituenti, koje se međusobno neovisno bira iz skupine koju čine karboksi, aminokarbonil i (C1-C4)-alkil,
gdje pak alkil može biti supstituiran sa supstituentom kojeg se bira iz skupine koju čine hidroksi, karboksi i aminokarbonil,
Y predstavlja vezu, O, NH ili S,
A predstavlja (C6-C10)-aril ili 5- do 10-eročlani heteroaril,
gdje su aril i heteroaril supstituirani sa supstituentom sljedeće formule
[image]
ili
[image]
,
gdje
R1b, R2b i R3b međusobno neovisno predstavljaju vodik, amino, hidroksi, (C1-C4)-alkil, (C1-C4)-alkoksi, (C3-C6)-cikloalkil, 4-, 5- 6- ili 7-eročlani heterociklil ili 5- ili 6-eročlani heteroaril,
gdje amino i hidroksi mogu biti supstituirani s jednim ili dva supstituenta, koje se međusobno neovisno bira iz skupine koju čine karbonil, (C1-C4)-alkilkarbonil, mono- ili di-(C1-C4)-alkilaminokarbonil, te (C1-C4)-alkil,
gdje alkoksi, heterociklil i heteroaril mogu biti supstituirani s jednim, dva ili tri supstituenta koje se međusobno neovisno bira iz skupine koju čine halogen, hidroksi, amino, karbonil, karboksi, (C1-C4)-alkilkarbonil, (C1-C4)-alkoksi, mono- ili di-(C1-C4)-alkilamino, mono- ili di-(C1-C4)-alkilaminokarbonil, -NH-CH(=NH), -NH-C(=NH)(NH2),-C(=NH)CH3 i (C1-C4)-alkil, i
gdje alkil i cikloalkil mogu biti supstituirani s jednim, dva ili tri supstituenta koje se međusobno neovisno bira iz skupine koju čine halogen, hidroksi, amino, karbonil, karboksi, karboniloksi, aminokarbonil, karbonilamino, (C1-C4)-alkilkarbonil, (C1-C4)-alkoksi, mono- ili di-(C1-C4)-alkilamino, mono- ili di-(C1-C4)-alkilaminokarbonil, -NH-CH(=NH), -NH-C(=NH)(NH2), -CH(=NH)CH3, (C6-C10)-aril, 5- ili 6-eročlani heteroaril i 5- ili 6-eročlani heterociklil,
gdje pak heteroaril i heterociklil mogu biti supstituirani s (C1-C4)-alkilom, i
gdje pak amino može biti supstituiran s 5- ili 6-eročlanim heteroarilom, ili
R2b i R3b zajedno s atomom dušika na kojeg su vezani tvore 5- do 7-eročlani heterocikl koji sadrži jedan, dva ili tri dodatna heteroatoma koji se bira iz niza N, O i S, a R1b je definiran kao gore,
R4b predstavlja vodik, amino, hidroksi, (C1-C4)-alkil ili (C1-C4)-alkoksi,
gdje amino i hidroksi mogu biti supstituirani s jednim ili dva supstituenta, koje se međusobno neovisno bira iz skupine koju čine (C1-C4)-alkilkarbonil, mono- ili di-(C1-C4)-alkilaminokarbonil i (C1-C4)-alkil,
gdje alkoksi može biti supstituiran s jednim, dva ili tri supstituenta koje se međusobno neovisno bira iz skupine koju čine halogen, hidroksi, amino, karbonil, karboksi, (C1-C4)-alkilkarbonil, (C1-C4)-alkoksi, mono- ili di-(C1-C4)-alkilamino, mono- ili di-(C1-C4)-alkilaminokarbonil, -NHCH(=NH),-NH-C(=NH)(NH2), -CH(=NH)CH3 i (C1-C4)-alkil, i
gdje alkil može biti supstituiran s jednim, dva ili tri supstituenta koje se međusobno neovisno bira iz skupine koju čine halogen, hidroksi, amino, karbonil, karboksi, aminokarbonil, (C1-C4)-alkilkarbonil, (C1-C4)-alkoksi, mono- ili di-(C1-C4)-alkilamino, mono- ili di-(C1-C4)-alkilaminokarbonil, -NH-CH(=NH), -NH-C(=NH)(NH2), -CH(=NH)CH3, (C1-C4)-alkil, (C6-C10)-aril i 5- ili 6-eročlani heteroaril,
R5b predstavlja vodik ili (C1-C4)-alkil,
Q predstavlja vezu, CH2 ili NH,
k predstavlja cijeli broj 1 ili 2, i
* je mjesto vezanja na ostatak kojeg predstavlja A, i
gdje aril i heteroaril mogu biti dodatno supstituirani s jednim ili dva supstituenta, koje se međusobno neovisno bira iz skupine koju čine halogen, cijano, amino, hidroksi, (C1-C4)-alkil, (C1-C4)-alkoksi, mono- ili di-(C1-C4)-alkilamino, amino-(C1-C4)-alkil, hidroksi-(C1-C4)-alkil ili karboksi,
gdje pak alkil, alkoksi, alkilamino, aminoalkil, hidroksialkil i karboksi mogu biti supstituirani sa supstituentom kojeg se bira iz skupine koju čine halogen, (C1-C4)-alkil i karbonil, i
I predstavlja cijeli broj 0, 1, 2 ili 3,
i njegove soli, njegovi solvati i solvati njegovih soli.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što
R1 i R2 međusobno neovisno predstavljaju vodik ili (C1-C4)-alkil, ili
R1 i R2 zajedno s atomom ugljika na kojeg su vezani tvore (C3-C8)-cikloalkil,
R3 predstavlja -(CH2)m-(SO2)OH ili -O-(CH2)o-(SO2)OH,
gdje m i o međusobno neovisno predstavljaju cijeli broj 0 ili 1 i
gdje bilo koja skupina CH2 koja se nalazi u ostacima koje predstavlja R3 može biti supstituirana s jednim ili dva (C1-C4)-alkilna ostatka,
X predstavlja CR4 ili N,
R4 predstavlja vodik ili halogen,
Z predstavlja vezu ili alkilni lanac s jednim, dva ili tri atoma ugljika,
gdje alkilni lanac može biti supstituiran s jednim, dva ili tri supstituenta, koje se međusobno neovisno bira iz skupine koju čine karboksi, aminokarbonil i (C1-C4)-alkil,
gdje pak alkil može biti supstituiran sa supstituentom kojeg se bira iz skupine koju čine hidroksi i karboksi,
Y predstavlja vezu, O, NH ili S,
A predstavlja (C6-C10)-aril ili 5- do 10-eročlani heteroaril,
gdje su aril i heteroaril supstituirani sa supstituentom sljedeće formule
[image]
ili
[image]
,
gdje
R1b, R2b i R3b međusobno neovisno predstavljaju vodik, amino, hidroksi, (C1-C4)-alkil, 4-, 5-, 6- ili 7-eročlani heterociklil ili 5- ili 6-eročlani heteroaril,
gdje heterociklil i heteroaril mogu biti supstituirani s jednim, dva ili tri supstituenta koje se međusobno neovisno bira iz skupine koju čine halogen, hidroksi, amino, karbonil, karboksi, (C1-C4)-alkilkarbonil, (C1-C4)-alkoksi, mono- ili di-(C1-C4)-alkilamino, mono- ili di-(C1-C4)-alkilaminokarbonil, -NH-CH(=NH), -NH-C(=NH)(NH2),-C(=NH)CH3 i (C1-C4)-alkil, i
gdje alkil može biti supstituiran s jednim, dva ili tri supstituenta koje se međusobno neovisno bira iz skupine koju čine halogen, hidroksi, amino, karbonil, karboksi, karboniloksi, aminokarbonil, karbonilamino, (C1-C4)-alkilkarbonil, (C1-C4)-alkoksi, mono- ili di-(C1-C4)-alkilamino, mono- ili di-(C1-C4)-alkilaminokarbonil, -NH-CH(=NH),-NH-C(=NH)(NH2), -CH(=NH)CH3, (C6-C10)-aril, 5- ili 6-eročlani heteroaril i 5- ili 6-eročlani heterociklil,
gdje pak heteroaril i heterociklil mogu biti supstituirani s (C1-C4)-alkilom ili
R2b i R3b zajedno s atomom dušika na kojeg su vezani tvore 5- do 7-eročlani heterocikl koji sadrži jedan, dva ili tri dodatna heteroatoma koji se bira iz niza N, O i S, a R1b je definiran kao gore,
R4b predstavlja vodik, amino, hidroksi, (C1-C4)-alkil ili (C1-C4)-alkoksi,
gdje amino i hidroksi mogu biti supstituirani s jednim ili dva supstituenta, koje se međusobno neovisno bira iz skupine koju čine (C1-C4)-alkilkarbonil, mono- ili di-(C1-C4)-alkilaminokarbonil i (C1-C4)-alkil, i
gdje alkil može biti supstituiran s jednim, dva ili tri supstituenta koje se međusobno neovisno bira iz skupine koju čine halogen, hidroksi, amino, karbonil, karboksi, aminokarbonil, (C1-C4)-alkilkarbonil, (C1-C4)-alkoksi, mono- ili di-(C1-C4)-alkilamino, mono- ili di-(C1-C4)-alkilaminokarbonil, -NH-CH(=NH), -NH-C(=NH)(NH2), -CH(=NH)CH3, (C1-C4)-alkil, (C6-C10)-aril i 5- ili 6-eročlani heteroaril,
R5b predstavlja vodik ili (C1-C4)-alkil,
Q predstavlja vezu, CH2 ili NH,
k predstavlja cijeli broj 1 ili 2, i
* je mjesto vezanja na ostatak kojeg predstavlja A, i
gdje aril i heteroaril mogu biti dodatno supstituirani s jednim ili dva supstituenta, koje se međusobno neovisno bira iz skupine koju čine halogen, cijano, amino, hidroksi, (C1-C4)-alkil, (C1-C4)-alkoksi, mono- ili di-(C1-C4)-alkilamino, amino-(C1-C4)-alkil, hidroksi-(C1-C4)-alkil ili karboksi,
gdje pak alkil, alkoksi, alkilamino, aminoalkil, hidroksialkil i karboksi mogu biti supstituirani sa supstituentom kojeg se bira iz skupine koju čine halogen, (C1-C4)-alkil i karbonil, i
I predstavlja cijeli broj 0 ili 1
i njegove soli, njegovi solvati i solvati njegovih soli.
3. Spoj u skladu s patentnim zahtjevom 1 ili 2, naznačen time što
R1 i R2 međusobno neovisno predstavljaju vodik ili (C1-C4)-alkil, ili
R1 i R2 zajedno s atomom ugljika na kojeg su vezani tvore (C3-C8)-cikloalkil,
R3 predstavlja -(SO2)OH ili -O-(CH2)o-(SO2)OH,
gdje je o cijeli broj 0 ili 1, i
gdje bilo koja skupina CH2 koja se nalazi u ostacima koje predstavlja R3 može biti supstituirana s jednim ili dva (C1-C4)-alkilna ostatka,
X predstavlja CH,
Z predstavlja alkilni lanac s dva ili tri atoma ugljika,
gdje alkilni lanac može biti supstituiran s jednim ili dva supstituenta, koje se međusobno neovisno bira iz skupine koju čine karboksi, aminokarbonil, metil, hidroksimetil, hidroksietil,
Y predstavlja O,
A predstavlja fenil ili 5- ili 6-eročlani heteroaril,
gdje su fenil i heteroaril supstituirani sa supstituentom sljedeće formule
[image]
ili
[image]
,
gdje
R1b, R2b i R3b međusobno neovisno predstavljaju vodik, amino, hidroksi, (C1-C4)-alkil ili 4-, 5-, 6- ili 7-eročlani heterociklil,
gdje heterociklil može biti supstituiran s jednim ili dva supstituenta, koje se međusobno neovisno bira iz skupine koju čine amino, karboksi, mono- ili di-(C1-C4)-alkilamino, te (C1-C4)-alkil, i
gdje alkil može biti supstituiran s jednim ili dva supstituenta, koje se međusobno neovisno bira iz skupine koju čine hidroksi, amino, karboksi, karboniloksi, aminokarbonil, karbonilamino, mono- ili di-(C1-C4)-alkilamino, mono- ili di-(C1-C4)-alkilaminokarbonil, -NH-CH(=NH), -NHC(=NH)-(NH2), fenil, 6-eročlani heteroaril i 5- ili 6-eročlani heterociklil, ili,
R2b i R3b zajedno s atomom dušika na kojeg su vezani tvore 6-eročlani heterocikl koji sadrži jedan ili dva atomi dušika, a R1b je vodik,
R4b predstavlja vodik ili amino,
gdje amino može biti supstituiran s jednim ili dva (C1-C4)-alkilna supstituenta,
R5b predstavlja vodik,
Q predstavlja vezu,
k predstavlja cijeli broj 1 ili 2, i
* je mjesto vezanja na ostatak kojeg predstavlja A, te gdje fenil i heteroaril mogu biti dodatno supstituirani s jednim ili dva supstituenta, koje se međusobno neovisno bira iz skupine koju čine halogen, cijano, amino, hidroksi, (C1-C4)-alkil ili hidroksi-(C1-C4)-alkil,
gdje pak hidroksialkil može biti supstituiran s karbonilnim supstituentom, i
I predstavlja 0
i njegove soli, njegovi solvati i solvati njegovih soli.
4. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što
R1 i R2 međusobno neovisno predstavljaju vodik ili metil,
R3 predstavlja -(SO2)OH ili -O-(SO2)OH,
X predstavlja CH,
Z predstavlja alkilni lanac s dva ili tri atoma ugljika,
gdje alkilni lanac može biti supstituiran s jednim ili dva supstituenta, koje se međusobno neovisno bira iz skupine koju čine karboksi i metil,
Y predstavlja O,
A predstavlja fenil ili 6-eročlani heteroaril,
gdje su fenil i heteroaril supstituirani sa supstituentom sljedeće formule
[image]
,
gdje
R1b i R2b predstavljaju vodik,
R3b predstavlja vodik, amino, hidroksi, (C1-C4)-alkil ili 4-, 5- ili 6-eročlani heterociklil koji sadrži dušik,
gdje alkil može biti supstituiran sa supstituentom kojeg se bira iz skupine koju čine hidroksi, amino, karboksi, karboniloksi, mono- ili di-(C1-C4)-alkilamino, -NH-CH(=NH), -NH-C(=NH)(NH2), 5- ili 6-eročlani heteroaril koji sadrži dušik i 5- ili 6-eročlani heterociklil koji sadrži dušik,
Q predstavlja vezu,
* je mjesto vezanja na ostatak kojeg predstavlja A, i
gdje aril i heteroaril mogu biti dodatno supstituirani s jednim supstituentom kojeg se bira iz skupine koju čine halogen, cijano, amino, hidroksi, (C1-C4)-alkil ili hidroksi-(C1-C4)-alkil, i
I predstavlja 0
i njegove soli, njegovi solvati i solvati njegovih soli.
5. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što
R1 i R2 predstavljaju metil,
R3 predstavlja -O-(SO2)OH,
X predstavlja CH,
Z predstavlja alkilni lanac s dva atoma ugljika,
gdje alkilni lanac može biti supstituiran s karboksi supstituentom,
Y predstavlja O,
A predstavlja fenil supstituiran sa supstituentom sljedeće formule
[image]
,
gdje
R1b i R2b predstavljaju vodik,
R3b predstavlja aminoetil, azetidin, pirolidin ili piperidin,
Q predstavlja vezu,
* je mjesto vezanja na ostatak kojeg predstavlja A, i
I predstavlja 0
i njegove soli, njegovi solvati i solvati njegovih soli.
6. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što
R1 i R2 predstavljaju metil,
R3 predstavlja -O-(SO2)OH,
X predstavlja CH,
Z predstavlja alkilni lanac s dva ugljika, supstituiran s karboksi supstituentom,
Y predstavlja O,
A predstavlja fenil supstituiran sa supstituentom sljedeće formule
[image]
,
gdje
R1b i R2b predstavljaju vodik,
R3b predstavlja aminoetil, azetidin, pirolidin ili piperidin,
Q predstavlja vezu,
* je mjesto vezanja na ostatak kojeg predstavlja A, i
I predstavlja 0
i njegove soli, njegovi solvati i solvati njegovih soli.
7. Spoj u skladu s patentnim zahtjevom 1, naznačen time što A predstavlja skupinu koju se bira između sljedećih formula
[image]
[image]
[image]
[image]
[image]
i njihovih soli, njihovih solvata i solvata njihovih soli.
8. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je navedeni spoj
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(4-karbamimidoil-3-hidroksifenoksi)etoksi]imino}-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(4-karbamimidoil-3-hidroksifenoksi)etoksi]imino}acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[(6-karbamimidoilpiridin-3-il)oksi]etoksi}imino)acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[(6-karbamimidoilpiridin-3-il)oksi]etoksi}imino)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[(5-karbamimidoilpiridin-2-il)oksi]etoksi}imino)acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[(4-karbamimidoilfenil)sulfanil]etoksi}imino)acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[(4-karbamimidoilfenil)sulfanil]etoksi}imino)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[(4-karbamimidoilfenil)amino]etoksi}imino)acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(4-karbamimidoilfenoksi)etoksi]imino}acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(4-karbamimidoilfenoksi)etoksi]imino}-N-[(2R,3S)-2-metil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2R,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(4-karbamimidoilfenoksi)etoksi]imino}acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
{[(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(4-karbamimidoilfenoksi)etoksi]imino}acetil]amino}-2-metil-4-oksoazetidin-1-il]oksi}metansulfonska kiselina
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(4-karbamimidoil-3-metilfenoksi)etoksi]imino}-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(4-karbamimidoil-3-metilfenoksi)etoksi]imino}acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[(2-karbamimidoilpiridin-4-il)oksi]etoksi}imino)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(4-karbamimidoilfenoksi)etoksi]imino}-N-[2-okso-1-(sulfooksi)-1-azaspiro[3.4]okt-3-il]etanamid
(25,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(4-karbamimidoilfenoksi)-2-metilpropoksi]imino}acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({[1-(4-karbamimidoilfenoksi)-2-metilpropan-2-il]oksi}imino)acetil]amino}2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(4-karbamimidoil-2-fluorfenoksi)etoksi]imino}acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(4-karbamimidoil-2-klorfenoksi)etoksi]imino}acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[4-(N-hidroksikarbamimidoil)fenoksi]etoksi}imino)acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[(4-karbamimidoilpiridin-2-il)oksi]etoksi}imino)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2Z)-2-(2-amino-1,3-tiazol-4-il)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]-2-[(2-{4-[N-(piperidin-4-il)karbamimidoil]fenoksi}etoksi)imino]etanamid
(2Z)-2-[(2-{4-[N-(2-aminoetil)karbamimidoil]fenoksi}etoksi)imino]-2-(2-amino-1,3-tiazol-4-il)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[4-(4,5-dihidro-1H-imidazol-2-il)fenoksi]etoksi}imino)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2S i 2R)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(2S,3S)-2-metil-4-okso-1-sulfoazetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-(4-karbamidinoil-fenoksi)propanska kiselina
(2S i 2R)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-(4-karbamimidoil-fenoksi)propanska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[(6-karbamimidoilpiridazin-3-il)oksi]etoksi}imino)acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2Z)-2-(2-amino-1,3-tiazo)-4-il)-2-({2-[(6-karbamimidoilpiridazin-3-il)oksi]etoksi}imino)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[(5-karbamimidoilpirazin-2-il)oksi]etoksi}imino)acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[(4-karbamimidoil-1,3-tiazol-2-il)oksi]etoksi}imino)acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-(2-[(4-karbamimidoiltiofen-2-il)metoksi]imino)acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[(6-karbamimidoil-5-hidroksipiridin-3-il)oksi]etoksi}imino)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2S i 2R)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-(4-karbamimidoil-3-hidroksifenoksi)propanska kiselina
(2S,3S)-3-{[(2Z)-2-{[2-(2-amino-4-karbamimidoilfenoksi)etoksi]imino}-2-(2-amino-1,3-tiazol-4-il)acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S i 2R)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-[(6-karbamimidoilpiridin-3-il)oksi]propanska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-[{3-(4-karbamimidoilfenoksi)propoksi]imino}acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2Z)-2-(2-amino-1,3-tiazol-4-il)-N-[(3S)-1-hidroksi-2,2-dimetil-4-oksoazetidin-3-il]-2-({2-[4-(N-{2-[(iminometil)amino]etil}karbamimidoil)fenoksi]etoksi}imino)etanamid
(2Z)-2-(2-amino-1,3-tiazol-4-il)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]-2-{[2-(4-{N-[(3S)-pirolidin-3-il]karbamimidoil}fenoksi)etoksi]imino}etanamid
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(4-{N-[2-(dimetilamino)etil]karbamimidoil}fenoksi)etoksi]imino}-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(4-karbamimidoilfenoksi)etoksi]imino}-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(4S)-4-{[{4-[2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)etoksi]fenil}(amino)metil]amino}-N,N-dimetil-l-prolinamid
(2Z)-2-(2-amino-1,3-tiazol-4-il)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]-2-{[2-(4-{N-[(3S)-1-etanimidoilpirolidin-3-il]karbamimidoil}fenoksi)etoksi]imino}etanamid
(2R i 2S)-3-{4-[N-(2-aminoetil)karbamimidoil]fenoksi}-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)propanska kiselina
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({[(2R i 2S)-1-(4-karbamimidoilfenoksi)-3-hidroksipropan-2-il]oksi}imino)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
3-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-4-(4-karbamimidoilfenoksi)butanska kiselina
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(4-karbamimidoilfenoksi)etoksi]imino}-N-[(2S,3S)-2-metil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2R,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[3-(4-karbamimidoilfenoksi)propoksi]imino}acetil]amino}-2--4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(2-brom-4-karbamimidoilfenoksi)etoksi]imino}acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(4-karbamimidamidofenoksi)etoksi]imino}acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[3-(4-karbamimidamidofenoksi)propoksi]imino}acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2Z)-2-(5-amino-1,2,4-tiadiazol-3-il)-2-{[2-(4-karbamimidoilfenoksi)etoksi]imino}-N-[(25,3S)-1-hidroksi-2-metil-4-oksoazetidin-3-il]etanamid
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(3-karbamimidoilfenoksi)etoksi]imino}acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-({(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-[(2-{4-[N-(propan-2-il)karbamimidoil]fenoksi}etoksi)imino]acetil}amino)-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[(4-karbamimidoilbenzil)oksi]imino}acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[(4-karbamimidoiltiofen-2-il)metoksi]etoksi}imino)acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[(4-karbamimidoilbenzil)oksi]imino}-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[3-(4-karbamimidoilfenoksi)propoksi]imino}-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[4-karbamimidoil-2-(hidroksimetil)fenoksi]etoksi}imino)acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-({(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-[(2-{4-karbamimidoil-2-[(formiloksi)metil]fenoksi}etoksi)imino]acetil}amino)-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-5-klor-1,3-tiazol-4-il)-2-{[2-(4-karbamimidoilfenoksi)etoksi]imino}acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-({2-[4-(2-amino-2-iminoetil)fenoksi]etoksi}imino)-2-(2-amino-1,3-tiazol-4-il)acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-({(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-[(2-{4-[(2-formilhidrazinil)(imino)metil]fenoksi}etoksi)imino]acetil}amino)-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-({(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-[(2-{4-[hidrazinil(imino)metil]fenoksi}etoksi)imino]acetil}amino)-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[(5-karbamimidoil-1,3,4-tiadiazol-2-il)oksi]etoksi}imino)acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(4-karbamimidoilfenoksi)etoksi]imino}acetil]amino}-2-karbamoil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[(3-karbamimidoil-1,2-oksazol-5-il)oksi]etoksi}imino)acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(25,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[4-(N-metilkarbamimidoil)fenoksi]etoksi}imino)acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-({(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-[(2-{4-[N-(2-hidroksietil)karbamimidoil]fenoksi}etoksi)imino]acetil}amino)-2-metil-4-oksoazetidin-1-sulfonska kiselina
(25,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[2-(4-{N-[2-(formiloksi)etil]karbamidoil}fenoksi)etoksi]imino}acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[(3-karbamimidoil-1-metil-1H-pirazol-5-il)oksi]etoksi}imino)acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
(2S,3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[(5-karbamimidoil-1-metil-1H-pirazol-3-il)oksi]etoksi}imino)acetil]amino}-2-metil-4-oksoazetidin-1-sulfonska kiselina
N-[{4-[2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)etoksi]fenil}(imino)metil]glicine
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({2-[(2-karbamimidoil-5-metil-1,3-tiazol-4-il)oksi]etoksi}imino)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-(4-karbamimidoilfenoksi)propanamid
(2Z)-2-(2-amino-1,3-tiazol-4-il)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]-2-[(2-{4-[N-(piridin-2-ilmetil)karbamimidoil]fenoksi}etoksi)imino]etanamid
{[(2S,3S)-3-{[(2Z)-2-[(2-{4-[N-(2-aminoetil)karbamimidoil]fenoksi}etoksi)imino]-2-(2-amino-1,3-tiazol-4-il)acetil]amino}-2-metil-4-oksoazetidin-1-il]oksi}metansulfonska kiselina
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-[(2-{4-[N-(2-karbamimidamidoetil)karbamimidoil]fenoksi}etoksi)imino]-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
1-(2-{[{4-[2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)etoksi]fenil}(imino)metil]amino}etil)-1-metilpirolidimum kloride
(2Z)-2-(2-amino-1,3-tiazol-4-il)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]-2-[(2-{4-[imino(piperazin-1-il)metil]fenoksi}etoksi)imino etanamid
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-({[1-(4-karbamimidoilfenoksi)-(2R i 2S)-4-hidroksibutan-2-il]oksi}imino)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2Z)-2-{[2-({6-[N-(2-aminoetil)karbamimidoil]piridin-3-il}oksi)etoksi]immo}-2-(2-amino-1,3-tiazol-4-il)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2Z)-2-[(2-{4-[N-(3-aminopropil)karbamimidoil]fenoksi}etoksi)imino]-2-(2-amino-1,3-tiazol-4-il)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-[(2-{4-[N-(1,3-diaminopropan-2-il)karbamimidoil]fenoksi}etoksi)imino]-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2Z)-2-{[2-(4-{N-[(2R)-1-amino-3-hidroksipropan-2-il]karbamimidoil}fenoksi)etoksi]imino}-2-(2-amino-1,3-tiazol-4-il)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2Z)-2-({2-[4-(5-amino-1,4,5,6-tetrahidropirimidin-2-il)fenoksi]etoksi}imino)-2-(2-amino-1,3-tiazol-4-il)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(2R i 2S)-3-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-2-(4-karbamimidoilfenoksi)propanska kiselina
(2S)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-(4-{N-[(3R)-piperidin-3-il]karbamimidoil}fenoksi)propanska kiselina
(2R)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-(4-{N-[(3R)-piperidin-3-il]karbamimidoil}fenoksi)propanska kiselina
{[(3S)-3-{[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[(4-karbamimidoilbenzil)oksi]imino}acetil]amino}-2,2-dimetil-4-oksoazetidin-1-il]oksi}metansulfonska kiselina
(2Z)-2-[(2-{4-[5-(aminometil)-4,5-dihidro-1H-imidazol-2-il]fenoksi}etoksi)imino]-2-(2-amino-1,3-tiazol-4-il)-N-[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]etanamid
(3S)-3-({(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-[(2-{4-[N-(pirazolidin-4-il)karbamimidoil]fenoksi}etoksi)imino]acetil}amino)-2,2-dimetil-4-oksoazetidin-1-sulfonska kiselina
(2S)-2-({[(1Z)-1-{2-amino-1,3-tiazol-4-il}-2-{[(3S)-2,2-dimetil-4-okso-1-sulfoazetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-(4-{N-[(3S)-pirolidin-3-il]karbamimidoil}fenoksi)propanska kiselina
(2S)-3-{4-[N-(2-amino-2-metilpropil)karbamimidoil]fenoksi}-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)propanska kiselina
(2S)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-(4-{N-[2-(metilamino)etil]karbamimidoil}fenoksi)propanska kiselina
(2S)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-sulfoazetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-(4-{N-[(3R)-pirolidin-3-il]karbamimidoil}fenoksi)propanska kiselina
(2S)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-{4-[N-(piperidin-3-il)karbamimidoil]fenoksi}propanska kiselina
(2S)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-{4-[N-(pirolidin-2-ilmetil)karbamimidoil]fenoksi}propanska kiselina
(2S)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-{4-[N-(piperidin-2-ilmetil)karbamimidoil]fenoksi}propanska kiselina
(2S)-3-{4-[N-(trans-(R,R i S,S)-2-aminociklopropil)karbamimidoil]fenoksi}-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(33S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)propanska kiselina
(2S)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-sulfoazetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-(4-{N-[(3S)-1-metilpirolidin-3-il]karbamimidoil}fenoksi)propanska kiselina
(2S)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-{4-[N-(1,3-diaminopropan-2-il)karbamimidoil]fenoksi}propanska kiselina
(2R)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-{4-[N-(1,3-diaminopropan-2-il)karbamimidoil]fenoksi}propanska kiselina
(2S)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-{4-[N-(1H-imidazol-2-ilmetil)karbamimidoil]fenoksi}propanska kiselina
(2R)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-{4-[N-(1H-imidazol-2-ilmetil)karbamimidoil]fenoksi}propanska kiselina
(2S)-3-{4-[N-(4-aminopirolidin-3-il)karbamimidoil]fenoksi}-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)propanska kiselina
(2S)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-{4-[N-(azetidin-3-il)karbamimidoil]fenoksi}propanska kiselina
(2S)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-{4-[N-(piperidin-4-il)karbamimidoil]fenoksi}propanska kiselina
(2S)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-{4-[N-(azetidin-3-il)karbamimidoil]fenoksi}propanska kiselina
(2S)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-(4-{N-[2-(pirimidin-2-ilamino)etil]karbamimidoil}fenoksi)propanska kiselina
(2R)-2-({[(1Z)-1-(2-amino-1,3-tiazol-4-il)-2-{[(3S)-2,2-dimetil-4-okso-1-(sulfooksi)azetidin-3-il]amino}-2-oksoetiliden]amino}oksi)-3-(4-{N-[2-(pirimidin-2-ilamino)etil]karbamimidoil}fenoksi)propanska kiselina
i njihove soli, njihovi solvati i solvati njihovih soli.
9. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je namijenjen upotrebi u postupku liječenja i/ili sprječavanja bolesti.
10. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što su bolesti bakterijske infekcije.
11. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što se kod navedenih bakterijskih infekcija radi o infekcijama gram-negativnim bakterijama.
12. Postupak priprave spoja formule (I) u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u uklanjanju zaštitne skupine iz spoja formule
[image]
,
gdje Pg predstavlja zaštitnu skupinu, a R1-R3, A, I, X, Y i Z su definirani kao u patentnom zahtjevu 1.
13. Postupak u skladu s patentnim zahtjevom 12, naznačen time što se spoj (II) pripravlja reakcijom spoja formule
[image]
,
gdje Pg predstavlja zaštitnu skupinu, a A, I, X, Y i Z su definirani kao u patentnom zahtjevu 1, sa spojem formule
[image]
,
gdje su R1, R2 i R3 definirani kao u patentnom zahtjevu 1.
14. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje i/ili profilaksu bolesti.
15. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje i/ili profilaksu bakterijskih infekcija.
16. Medikament, naznačen time što sadrži najmanje jedan spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, u kombinaciji s najmanje jednim dodatnim aktivnim spojem.
17. Medikament u skladu s patentnim zahtjevom 16, naznačen time što je dodatni aktivni spoj inhibitor β-laktamaze.
18. Medikament, naznačen time što sadrži najmanje jedan spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, u kombinaciji s najmanje jednom inertnom, netoksičnom, farmaceutski prihvatljivom pomoćnom tvari.
19. Medikament u skladu s bilo kojim od patentnih zahtjeva 16 do 18, naznačen time što je namijenjen upotrebi u postupku liječenja i/ili sprječavanja bakterijskih infekcija.
20. Antibakterijski djelotvorna količina najmanje jednog spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 8, ili medikamenta u skladu s bilo kojim od patentnih zahtjeva 16 do 18, naznačena time što je namijenjena upotrebi u postupku kontroliranja bakterijskih infekcija kod ljudi i životinja.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12152279 | 2012-01-24 | ||
EP13701246.4A EP2806873B1 (en) | 2012-01-24 | 2013-01-23 | Amidine substituted beta-lactam compounds, their preparation and use as antibacterial agents |
PCT/EP2013/051217 WO2013110643A1 (en) | 2012-01-24 | 2013-01-23 | Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20161171T1 true HRP20161171T1 (hr) | 2016-11-04 |
Family
ID=47603723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20161171TT HRP20161171T1 (hr) | 2012-01-24 | 2016-09-13 | AMIDINSKI SUPSTITUIRANI β-LAKTAMSKI SPOJEVI, NJIHOVA PRIPRAVA I UPOTREBA KAO ANTIBAKTERIJSKIH SREDSTAVA |
Country Status (43)
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160326157A1 (en) * | 2014-01-06 | 2016-11-10 | President And Fellows Of Harvard College | Monobactams and methods of their synthesis and use |
SG11201606711UA (en) | 2014-03-24 | 2016-10-28 | Novartis Ag | Monobactam organic compounds for the treatment of bacterial infections |
CN105175335B (zh) * | 2015-08-13 | 2017-11-03 | 南阳师范学院 | 一种3‑(3,3‑二氯烯丙氧基)‑1‑甲基吡唑‑5‑甲酰胺衍生物及其制备方法 |
ES2817537T3 (es) * | 2015-09-23 | 2021-04-07 | Novartis Ag | Sales y formas sólidas de un antibiótico monobactámico |
KR20180093925A (ko) * | 2015-12-15 | 2018-08-22 | 머크 샤프 앤드 돔 코포레이션 | 박테리아 감염을 치료하기 위한 비아릴 모노박탐 화합물 및 그의 사용 방법 |
MX2018010878A (es) * | 2016-03-07 | 2018-11-09 | Merck Sharp & Dohme | Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas. |
CN107641119B (zh) | 2016-07-21 | 2019-11-08 | 中国科学院上海药物研究所 | 单环β-内酰胺-铁载体轭合物及其制备方法和用途 |
EP4223766A3 (en) | 2016-08-26 | 2023-10-18 | Codexis, Inc. | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
EP3541364A1 (en) | 2016-11-18 | 2019-09-25 | AiCuris Anti-infective Cures GmbH | Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions |
US20190328716A1 (en) * | 2016-11-18 | 2019-10-31 | Aicuris Anti-Infective Cures Gmbh | Liposomal formulations of amidine substituted beta-lactam compounds for use in the treatment of bacterial infections |
JP2020502210A (ja) * | 2016-12-21 | 2020-01-23 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 抗生物質耐性菌株による感染症向けのアミジン置換β−ラクタム化合物とβ−ラクタマーゼ阻害剤を用いた併用療法 |
CA3070010A1 (en) | 2017-07-18 | 2019-01-24 | Bayer Cropscience Aktiengesellschaft | Substituted 3-heteroaryloxy-1h-pyrazoles and salts thereof and their use as herbicidal active substances |
WO2019020810A1 (en) | 2017-07-28 | 2019-01-31 | Aicuris Anti-Infective Cures Gmbh | CRYSTALLINE FORM OF (2S) -2 - [[(Z) - [- 1- (2-AMINO-4-THIAZOLYL) -2 - [[(3S) -2,2-DIMETHYL-4-OXO] -Acid 1- (SULFOOXY) -3-AZETIDINYL] AMINO] -2-OXOETHYLIDENE] AMINO] OXY] -3- [4- [IMINO [(3R) -3-PIPERIDINYLAMINO] METHYL] PHENOXY] -PROPANOIC |
AU2018311521B2 (en) | 2017-08-02 | 2022-03-03 | Novartis Ag | Process for preparing 1 -(((Z)-(1 -(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-y l)methyl)-1 -sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropane carboxylic acid |
KR102455390B1 (ko) * | 2017-10-02 | 2022-10-17 | 아릭사 파마슈티컬스 인코포레이티드 | 아즈트레오남 유도체 및 이의 용도 |
AU2018345523B2 (en) * | 2017-10-02 | 2021-10-21 | Merck Sharp & Dohme Llc | Chromane monobactam compounds for the treatment of bacterial infections |
EP3747883A4 (en) * | 2018-01-29 | 2020-12-16 | Medshine Discovery Inc. | B-LACTAM MONOCYCLIC COMPOUND FOR TREATMENT OF BACTERIAL INFECTION |
US20220002288A1 (en) * | 2018-11-13 | 2022-01-06 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Monobactam compounds and use therefor |
EP3901150A4 (en) | 2018-12-18 | 2022-09-07 | Medshine Discovery Inc. | APPLICATION OF A MONOCYCLIC BETA-LACTAM COMPOUND IN PHARMACY |
CN111303144B (zh) * | 2019-12-13 | 2020-11-27 | 苏州信诺维医药科技有限公司 | 一种治疗细菌感染的化合物 |
WO2021121387A1 (zh) | 2019-12-19 | 2021-06-24 | 南京明德新药研发有限公司 | 化合物在制药中的应用 |
CN111253405B (zh) * | 2020-03-20 | 2022-12-16 | 南京安伦化工科技有限公司 | 一种比阿培南中间体的制备方法 |
CN111675641B (zh) * | 2020-06-04 | 2023-09-08 | 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) | 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法 |
CN111592536B (zh) * | 2020-06-04 | 2023-11-03 | 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) | 单环β-内酰胺化合物及其制备方法和应用 |
EP4165039A4 (en) * | 2020-07-16 | 2023-06-21 | Ningxia Academy of Agriculture and Forestry Sciences | MONOBACTAM COMPOUNDS, THEIR PRODUCTION AND USE AS ANTIBACTERIAL AGENTS |
US20230150996A1 (en) * | 2020-08-06 | 2023-05-18 | Ningxia Academy Of Agriculture And Forestry Sciences | B-lactam compounds, their preparation and use as antibacterial agents |
CN112079791A (zh) * | 2020-08-21 | 2020-12-15 | 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) | 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用 |
CN111909067B (zh) * | 2020-08-28 | 2022-03-15 | 浙江凯普化工有限公司 | 一种d-青霉胺的有机全合成方法 |
WO2023082055A1 (zh) * | 2021-11-09 | 2023-05-19 | 中国医学科学院医药生物技术研究所 | 包含β-内酰胺类化合物的药物组合物及其用途 |
WO2023091438A1 (en) | 2021-11-18 | 2023-05-25 | Merck Sharp & Dohme Llc | Chromane amidine monobactam antibiotics |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE794886A (fr) * | 1972-02-22 | 1973-08-02 | Pfizer | Acides 6-(alpha-(omega-guanidinoalcanoylamino)acylamino)-penicillaniques |
DE2458973A1 (de) * | 1974-12-13 | 1976-06-16 | Hoechst Ag | Acylaminopenicillansaeuren und verfahren zu ihrer herstellung |
DE2749265A1 (de) | 1977-11-03 | 1979-05-10 | Linde Ag | Verfahren zur biologischen reinigung von abwasser |
ZA806977B (en) * | 1979-11-19 | 1981-10-28 | Fujisawa Pharmaceutical Co | 7-acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof |
JPS58210061A (ja) * | 1982-05-31 | 1983-12-07 | Takeda Chem Ind Ltd | 1−スルホ−2−オキソアゼチジン誘導体、その製造法および用途 |
CA1262128A (en) | 1981-08-27 | 1989-10-03 | Christian N. Hubschwerlen | .beta.-lactams |
NZ205642A (en) | 1982-10-06 | 1986-08-08 | Squibb & Sons Inc | Beta-lactams and pharmaceutical compositions |
US4638060A (en) | 1985-04-29 | 1987-01-20 | E. R. Squibb & Sons, Inc. | O-sulfated spiro β-lactam hydroxamic acids |
JPH01290674A (ja) | 1988-04-04 | 1989-11-22 | E R Squibb & Sons Inc | アゼチジニル誘導体 |
US5112968A (en) | 1989-07-28 | 1992-05-12 | E. R. Squibb & Sons, Inc. | Monobactam hydrazide derivatives |
CA2024282A1 (en) | 1989-09-21 | 1991-03-22 | Peter H. Ermann | Heterocyclic hydrazide derivatives of monocyclic beta-lactam antibiotics |
ZA918014B (en) | 1990-11-05 | 1992-07-29 | Squibb & Sons Inc | Heteroaroyl derivatives of monocyclic beta-lactam antibiotics |
US5250691A (en) | 1991-09-09 | 1993-10-05 | E. R. Squibb & Sons, Inc. | Heteroaryl derivatives of monocyclic beta-lactam antibiotics |
US5994340A (en) * | 1997-08-29 | 1999-11-30 | Synphar Laboratories, Inc. | Azetidinone derivatives as β-lactamase inhibitors |
KR100854810B1 (ko) | 2000-09-14 | 2008-08-27 | 판데릭스 리미티드 | 항균제로서 3-(헤테로아릴아세트아미도)-2-옥소-아제티딘-1-술폰산 유도체 |
EP1711457A4 (en) | 2004-01-27 | 2008-01-09 | Merck Frosst Company | NITROGEN MONOXIDE RELEASING PRODRUGS OF DIARYL-2- (5H) FURANOES AS INHIBITORS OF CYCLOOXYGENASE-2 |
NZ567629A (en) | 2005-09-23 | 2011-08-26 | Ms Science Corp | Piperazine derivatives useful in the treatment of discorders of the central nervous system |
CN101410111B (zh) | 2005-12-07 | 2012-12-12 | 巴斯利尔药物股份公司 | 单环-内酰胺类抗生素与β-内酰胺酶抑制剂的有效的联合应用 |
CN101384556B (zh) | 2006-02-14 | 2012-06-20 | 庵原化学工业株式会社 | 5-烷氧基-4-羟基甲基吡唑化合物的制备方法 |
WO2007119511A1 (en) | 2006-03-16 | 2007-10-25 | Astellas Pharma Inc. | Cephem compounds and use as antimicrobial agents |
KR101320718B1 (ko) | 2007-03-23 | 2013-10-21 | 바실리어 파마슈티카 아게 | 세균 감염 치료용 조합 약제 |
WO2009049028A1 (en) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
KR20110086742A (ko) * | 2008-12-19 | 2011-07-29 | 화이자 인코포레이티드 | 모노카밤 |
-
2013
- 2013-01-22 UY UY0001034585A patent/UY34585A/es not_active Application Discontinuation
- 2013-01-23 NZ NZ626951A patent/NZ626951A/en not_active IP Right Cessation
- 2013-01-23 AP AP2014007880A patent/AP2014007880A0/xx unknown
- 2013-01-23 CA CA2862338A patent/CA2862338C/en not_active Expired - Fee Related
- 2013-01-23 PT PT137012464T patent/PT2806873T/pt unknown
- 2013-01-23 MX MX2014008915A patent/MX346602B/es active IP Right Grant
- 2013-01-23 ES ES13701246.4T patent/ES2592403T3/es active Active
- 2013-01-23 UA UAA201409319A patent/UA110880C2/uk unknown
- 2013-01-23 PL PL13701246.4T patent/PL2806873T3/pl unknown
- 2013-01-23 BR BR112014017968A patent/BR112014017968A8/pt not_active Application Discontinuation
- 2013-01-23 SI SI201330299A patent/SI2806873T1/sl unknown
- 2013-01-23 ME MEP-2016-191A patent/ME02532B/me unknown
- 2013-01-23 HU HUE13701246A patent/HUE030452T2/en unknown
- 2013-01-23 RS RS20160764A patent/RS55210B1/sr unknown
- 2013-01-23 CU CUP2014000090A patent/CU24273B1/xx unknown
- 2013-01-23 MY MYPI2014002088A patent/MY173843A/en unknown
- 2013-01-23 US US14/374,325 patent/US9556165B2/en active Active
- 2013-01-23 TW TW102102410A patent/TWI659953B/zh not_active IP Right Cessation
- 2013-01-23 PE PE2014001132A patent/PE20142345A1/es active IP Right Grant
- 2013-01-23 DK DK13701246.4T patent/DK2806873T3/en active
- 2013-01-23 KR KR1020147020410A patent/KR102036393B1/ko active IP Right Grant
- 2013-01-23 EA EA201400838A patent/EA027126B1/ru unknown
- 2013-01-23 AU AU2013211575A patent/AU2013211575B2/en not_active Ceased
- 2013-01-23 JP JP2014553696A patent/JP5869701B2/ja not_active Expired - Fee Related
- 2013-01-23 SG SG11201403930XA patent/SG11201403930XA/en unknown
- 2013-01-23 WO PCT/EP2013/051217 patent/WO2013110643A1/en active Application Filing
- 2013-01-23 CN CN201380016121.9A patent/CN104203237A/zh active Pending
- 2013-01-23 IN IN1640MUN2014 patent/IN2014MN01640A/en unknown
- 2013-01-23 LT LTEP13701246.4T patent/LT2806873T/lt unknown
- 2013-01-23 EP EP13701246.4A patent/EP2806873B1/en active Active
- 2013-01-24 AR ARP130100215A patent/AR089796A1/es unknown
-
2014
- 2014-07-08 TN TNP2014000297A patent/TN2014000297A1/fr unknown
- 2014-07-10 ZA ZA2014/05057A patent/ZA201405057B/en unknown
- 2014-07-22 PH PH12014501671A patent/PH12014501671B1/en unknown
- 2014-07-22 CO CO14158608A patent/CO7101240A2/es unknown
- 2014-07-22 EC ECIEPI201410249A patent/ECSP14010249A/es unknown
- 2014-07-24 IL IL233805A patent/IL233805A/en active IP Right Grant
- 2014-07-24 CL CL2014001956A patent/CL2014001956A1/es unknown
- 2014-08-08 MA MA37280A patent/MA35905B1/fr unknown
-
2015
- 2015-04-24 HK HK15104018.3A patent/HK1203389A1/zh not_active IP Right Cessation
-
2016
- 2016-08-30 CY CY20161100851T patent/CY1117955T1/el unknown
- 2016-09-13 HR HRP20161171TT patent/HRP20161171T1/hr unknown
- 2016-10-06 SM SM201600354T patent/SMT201600354B/it unknown
- 2016-12-19 US US15/382,986 patent/US9782390B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20161171T1 (hr) | AMIDINSKI SUPSTITUIRANI β-LAKTAMSKI SPOJEVI, NJIHOVA PRIPRAVA I UPOTREBA KAO ANTIBAKTERIJSKIH SREDSTAVA | |
RU2013143028A (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
ES2569528T3 (es) | 4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus | |
NZ610312A (en) | 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors | |
JP2009518317A5 (hr) | ||
RU2014142598A (ru) | Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в | |
HRP20140588T1 (hr) | Spojevi kondenziranog prstena i njihova uporaba | |
HRP20110018T1 (hr) | Derivati pirido(2,1-a)-izokinolina kao inhibitori dpp-iv | |
AR083339A1 (es) | Compuestos de quinazolina como bloqueadores de los canales de sodio | |
JP2002535323A5 (hr) | ||
HRP20120738T1 (hr) | Inhibitori kinaza akt i p70 s6 | |
JP2017530185A5 (hr) | ||
RU2348628C2 (ru) | Замещенные циклопропильной группой оксазолидиноновые антибиотики и их производные | |
RU2000128036A (ru) | Амидиновые соединения | |
JP2011503103A5 (hr) | ||
CA2672373A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
JP2017522374A5 (hr) | ||
SI2834239T1 (en) | Heterobicyclic compounds as inhibitors of beta-lactamase | |
RU2010138577A (ru) | ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3 | |
PE20080856A1 (es) | Inhibidores de metaloproteasas de matriz | |
RU2018103198A (ru) | Новые соединения циклического n-карбоксамида, применяемые в качестве гербицидов | |
CA2522024A1 (en) | Cgrp receptor antagonists | |
HRP20140252T1 (hr) | Derivati imidazola kao inhibitori kazeinske kinaze | |
ATE476431T1 (de) | Piperidin- und azetidinderivate als glyt1- inhibitoren | |
AR088548A1 (es) | Derivados pirazinicos utiles para tratar enfermedades del aparato cardiovascular y para el tratamiento y/o profilaxis del dolor |